Market Cap 556.77B
Revenue (ttm) 94.19B
Net Income (ttm) 26.80B
EPS (ttm) N/A
PE Ratio 21.56
Forward PE 19.99
Profit Margin 28.46%
Debt to Equity Ratio 0.46
Volume 6,228,821
Avg Vol 8,106,326
Day's Range N/A - N/A
Shares Out 2.41B
Stochastic %K 82%
Beta 0.26
Analysts Strong Sell
Price Target $260.46

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 732 524 0400
Website: www.jnj.com
Address:
One Johnson & Johnson Plaza, New Brunswick, United States
TraderDaKing
TraderDaKing Jun. 25 at 7:27 PM
$ELTP $PFE $JNJ $WEN News breaking............ Here we go !!! Some knows something...... Hold the Line. No Selling Wait until Next Week..... Earning are Monday...... and a major call is Tuesday.....
0 · Reply
BarkingPuppy
BarkingPuppy Jun. 25 at 7:25 PM
$ELTP $JNJ $PFE Look At this..... Big buying trying to get in....
0 · Reply
PittsburghTrader
PittsburghTrader Jun. 25 at 6:37 PM
$SMH kind of crazy signal that most risk on down today yet $SMH holding a bid while risk off trades like $JNJ & $MRK are also up strongly
0 · Reply
LevelsOwl
LevelsOwl Jun. 25 at 3:41 PM
$JNJ today: Buyers are stepping in while price remains above both the 50-day and 200-day moving averages, keeping the broader uptrend intact as long as $244 holds. What confirms strength: A stable hold above VWAP into the close signals continued demand and keeps pressure toward the $250$252 zone. What weakens it: A clean break below $244 would open the door for a pullback toward the $241 area where momentum may cool. Simple read: The trend remains constructive while price stays above key intraday support. Quick takeaway: Holding above $245 keeps the setup biased toward another push toward recent highs. Overall price action is stable and slightly under prior peaks, with upside continuation still possible if support holds.
0 · Reply
Estimize
Estimize Jun. 25 at 2:12 PM
Wall St is expecting 2.85 EPS for $JNJ Q2 [Reporting 07/15 BMO] http://www.estimize.com/intro/jnj?chart=historical&metric_name=eps&utm_cont
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 25 at 1:52 PM
$JNJ $LLY $MRK $PFE $SLS Pfizer needs this victory ✌️ NOW! ✌️🙏❤️‍🩹
0 · Reply
GettnFibbywIT
GettnFibbywIT Jun. 25 at 1:49 PM
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 25 at 1:49 PM
$JNJ $LLY $MRK $PFE $SLS Pfizer it is. ✌️🙏❤️‍🩹
0 · Reply
MarketLegendd
MarketLegendd Jun. 25 at 1:48 PM
$JNJ continues to expand its cardiovascular pipeline with the SkyRunner carotid IVL program. If successful, the platform could improve treatment options for patients with heavily calcified carotid arteries and further strengthen Johnson & Johnson's position in medtech. Innovation in large markets tends to attract attention, especially when it addresses an unmet clinical need.
0 · Reply
harmongreg
harmongreg Jun. 25 at 1:41 PM
sold to close $JNJ June 26 Exp 240/250 call spreads
0 · Reply
Latest News on JNJ
Johnson & Johnson presents first results from ENERGY study

2026-06-11T09:26:54.000Z - 14 days ago

Johnson & Johnson presents first results from ENERGY study


Johnson & Johnson to Buy Firefly Bio for $1 Billion

Jun 8, 2026, 9:01 AM EDT - 17 days ago

Johnson & Johnson to Buy Firefly Bio for $1 Billion


Johnson & Johnson to acquire Firefly Bio for $1B in cash

2026-06-08T12:14:56.000Z - 17 days ago

Johnson & Johnson to acquire Firefly Bio for $1B in cash


Johnson & Johnson to buy Firefly Bio for $1 billion

Jun 8, 2026, 8:08 AM EDT - 17 days ago

Johnson & Johnson to buy Firefly Bio for $1 billion


Johnson & Johnson says nipocalimab approved in China

May 21, 2026, 4:31 AM EDT - 5 weeks ago

Johnson & Johnson says nipocalimab approved in China


CVS to drop J&J's Stelara from its main formularies

May 5, 2026, 9:15 AM EDT - 7 weeks ago

CVS to drop J&J's Stelara from its main formularies

CVS


J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine

May 2, 2026, 4:00 AM EDT - 7 weeks ago

J&J's $1.7 Billion Drug Ushers in Age of Psychedelic Medicine


Why These 3 Forever Stocks Belong on Your Watchlist

Apr 28, 2026, 11:10 AM EDT - 2 months ago

Why These 3 Forever Stocks Belong on Your Watchlist

WMT XOM


J&J sees AI halving the time to generate drug development leads

Apr 27, 2026, 11:03 AM EDT - 2 months ago

J&J sees AI halving the time to generate drug development leads


Johnson & Johnson Transcript: AGM 2026

Apr 23, 2026, 10:00 AM EDT - 2 months ago

Johnson & Johnson Transcript: AGM 2026


TraderDaKing
TraderDaKing Jun. 25 at 7:27 PM
$ELTP $PFE $JNJ $WEN News breaking............ Here we go !!! Some knows something...... Hold the Line. No Selling Wait until Next Week..... Earning are Monday...... and a major call is Tuesday.....
0 · Reply
BarkingPuppy
BarkingPuppy Jun. 25 at 7:25 PM
$ELTP $JNJ $PFE Look At this..... Big buying trying to get in....
0 · Reply
PittsburghTrader
PittsburghTrader Jun. 25 at 6:37 PM
$SMH kind of crazy signal that most risk on down today yet $SMH holding a bid while risk off trades like $JNJ & $MRK are also up strongly
0 · Reply
LevelsOwl
LevelsOwl Jun. 25 at 3:41 PM
$JNJ today: Buyers are stepping in while price remains above both the 50-day and 200-day moving averages, keeping the broader uptrend intact as long as $244 holds. What confirms strength: A stable hold above VWAP into the close signals continued demand and keeps pressure toward the $250$252 zone. What weakens it: A clean break below $244 would open the door for a pullback toward the $241 area where momentum may cool. Simple read: The trend remains constructive while price stays above key intraday support. Quick takeaway: Holding above $245 keeps the setup biased toward another push toward recent highs. Overall price action is stable and slightly under prior peaks, with upside continuation still possible if support holds.
0 · Reply
Estimize
Estimize Jun. 25 at 2:12 PM
Wall St is expecting 2.85 EPS for $JNJ Q2 [Reporting 07/15 BMO] http://www.estimize.com/intro/jnj?chart=historical&metric_name=eps&utm_cont
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 25 at 1:52 PM
$JNJ $LLY $MRK $PFE $SLS Pfizer needs this victory ✌️ NOW! ✌️🙏❤️‍🩹
0 · Reply
GettnFibbywIT
GettnFibbywIT Jun. 25 at 1:49 PM
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 25 at 1:49 PM
$JNJ $LLY $MRK $PFE $SLS Pfizer it is. ✌️🙏❤️‍🩹
0 · Reply
MarketLegendd
MarketLegendd Jun. 25 at 1:48 PM
$JNJ continues to expand its cardiovascular pipeline with the SkyRunner carotid IVL program. If successful, the platform could improve treatment options for patients with heavily calcified carotid arteries and further strengthen Johnson & Johnson's position in medtech. Innovation in large markets tends to attract attention, especially when it addresses an unmet clinical need.
0 · Reply
harmongreg
harmongreg Jun. 25 at 1:41 PM
sold to close $JNJ June 26 Exp 240/250 call spreads
0 · Reply
ElliottwaveForecast
ElliottwaveForecast Jun. 25 at 12:26 PM
$JNJ favors rally in (1) from the #bluebox area and confirmed 5 swing higher in diagonal sequence It should remain supported above May-2026 low to continue rally towards 259.3 - 271.4 area in daily bull run. #Elliottwave #JNJ
0 · Reply
UltimateTrader_22
UltimateTrader_22 Jun. 25 at 11:49 AM
$AIMN The right network. The right context. @AimwellBIO Observer connects serious healthcare professionals to trusted signals, curated intelligence, and a verified network built for the future of healthcare. Apply free. Stay in the network. http://aimwellbio.com/observer-signup $AIMN #pharma $PFE $JNJ $MEDI
0 · Reply
cwEWF
cwEWF Jun. 25 at 11:48 AM
$JNJ confirms five swing higher from #blue box area as (1). It should continue rally targeting 259.3 - 271.4 area from #Bluebox to extend daily bull run #elliottwave #JNJ
0 · Reply
TheStockTraderHub
TheStockTraderHub Jun. 25 at 3:33 AM
$JNJ with a close above it's all time highs trendline resistance today, $250/$255+ on deck in coming days. Support: $235/$231
0 · Reply
TheStockReferee
TheStockReferee Jun. 24 at 9:59 PM
$MU this clown pumps this shit like it’s his job and it can’t even get to new highs. there’s more upside in $JNJ
1 · Reply
FutureScout
FutureScout Jun. 24 at 9:00 PM
$PG And here is our leadership emerging in Staples. Even better inflows than $JNJ which has actually performed better.
0 · Reply
Nasdaq_Frontier
Nasdaq_Frontier Jun. 24 at 8:46 PM
There is always a bull market somewhere. Industrials Financials Healthcare Real Estate Most traders ignore sector rotation until it's obvious. By then the easy money is gone. Here are the names I'm watching in each sector: Healthcare: $JNJ $ABBV $VRTX $QURE $HIMS ... I have exposure in Industrials. Finance and plenty of Healthcare stocks. Bookmark this. The leaders are quietly rotating while everyone's still watching the same 7 tech names.
1 · Reply
yellowstar16
yellowstar16 Jun. 24 at 6:57 PM
$JNJ https://seekingalpha.com/article/4917319-johnson-and-amp-johnson-not-every-dollar-needs-to-chase-the-ai-boom-upgrade
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 24 at 4:01 PM
$JNJ $LLY $MRK $PFE $SLS SLS and PFE NDA has already been signed, BO pending Top line Paradigm shifting data from GPS Regal Pivotal Registrational phase 3 Study. Pfizer and Sellas has been preparing for this since late November 2025. I expect 2 trading halts in the coming days and weeks ahead. 1st Top Line data = $120.00+ BO= $200.00+ ✌️🙏❤️‍🩹
2 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 24 at 3:50 PM
$JNJ $LLY $MRK $PFE $SLS Everything is lined up ready to go. 👇 ✌️🙏❤️‍🩹
1 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Jun. 24 at 3:42 PM
$JNJ $LLY $MRK $PFE $SLS Pfizer is in trouble, they need a victory now. 40+ days since last official PR by Sellas. Element of surprise is on Dr. Angelos Stergiou side. In the meantime Whales are gobbling up any loose shares from weak hands. Institutional whales had to hit ASK to get thier orders filled. Yes. I am back.👇✌️🙏❤️‍🩹
2 · Reply
dewmoore
dewmoore Jun. 24 at 3:19 PM
$SLS The 80th event is likely already locked in, and with Pfizer’s $43B Seagen ADC just failing its Phase 3 trial, Big Pharma is officially desperate for fresh oncology wins. The kicker? GPS isn't just a one-trick pony for AML—it’s a massive platform targeting WT1 across 20+ other cancers like Mesothelioma and Ovarian cancer. A positive Phase 3 readout here easily commands $5B to $15B in this market.With 196.6M shares outstanding, the buyout math goes crazy: • $5B buyout = $25.43/share • $10B buyout = $50.86/share* • $15B buyout = $76.29/share *GSK just dropped $10.6B cash to buy Nuvalent for its oncology pipeline. The gap between the current market cap and these milestone targets is sickkkkkkkkk! I'm not even talking about the shorts LOL woo hooo $LLY $PFE $JNJ $MRK
1 · Reply